{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:00Z","timestamp":1772165700292,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04068-5","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:40:38Z","timestamp":1744026038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Kenneth","family":"Brand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Landry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Mulhern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Braden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"1","key":"4068_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/ki.1996.2","volume":"49","author":"B Fontaine","year":"1996","unstructured":"Fontaine B, Lapie P, Plassart E, et al. Periodic paralysis and voltage-gated ion channels. Kidney Int. 1996;49(1):9\u201318. https:\/\/doi.org\/10.1038\/ki.1996.2.","journal-title":"Kidney Int"},{"key":"4068_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","volume":"128","author":"NK Smith","year":"2019","unstructured":"Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019;128:94\u2013105. https:\/\/doi.org\/10.1016\/j.neuint.2019.04.010.","journal-title":"Neurochem Int"},{"key":"4068_CR3","unstructured":"Myopathy of Hypokalemic Periodic Paralysis: An Electron Microscopic Study | JAMA Neurology | JAMA Network. Accessed 4 Apr, 2024. https:\/\/jamanetwork.com\/journals\/jamaneurology\/article-abstract\/568933"},{"key":"4068_CR4","unstructured":"Progressive Myopathy in Hyperkalemic Periodic Paralysis | JAMA Neurology | JAMA Network. Accessed 4 Apr, 2024. https:\/\/jamanetwork.com\/journals\/jamaneurology\/article-abstract\/590332"},{"key":"4068_CR5","unstructured":"Sekhon DS, Vaqar S, Gupta V. Hyperkalemic Periodic Paralysis. In: StatPearls. StatPearls Publishing; 2024. Accessed 4 Apr, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564319\/"},{"issue":"9","key":"4068_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.braindev.2018.05.011","volume":"40","author":"Y Akaba","year":"2018","unstructured":"Akaba Y, Takahashi S, Sasaki Y, Kajino H. Successful treatment of normokalemic periodic paralysis with hydrochlorothiazide. Brain Dev. 2018;40(9):833\u20136. https:\/\/doi.org\/10.1016\/j.braindev.2018.05.011.","journal-title":"Brain Dev"},{"issue":"13","key":"4068_CR7","doi-asserted-by":"publisher","first-page":"8723","DOI":"10.1074\/jbc.M706105200","volume":"283","author":"Z Liu","year":"2008","unstructured":"Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem. 2008;283(13):8723\u201335. https:\/\/doi.org\/10.1074\/jbc.M706105200.","journal-title":"J Biol Chem"},{"issue":"1","key":"4068_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40200-022-01175-0","volume":"22","author":"W Xu","year":"2023","unstructured":"Xu W, Sang YQ, Liu XK, et al. Effect of glucagon-like peptide-1 receptor agonist on insulin secretion index and serum Wnt5a protein in patients with new-onset type 2 diabetes mellitus. J Diabetes Metab Disord. 2023;22(1):539\u201345. https:\/\/doi.org\/10.1007\/s40200-022-01175-0.","journal-title":"J Diabetes Metab Disord"},{"issue":"5","key":"4068_CR9","doi-asserted-by":"publisher","first-page":"R1126","DOI":"10.1152\/ajpregu.00687.2010","volume":"300","author":"HM Chan","year":"2011","unstructured":"Chan HM, Jain R, Ahr\u00e9n B, Pacini G, D\u2019Argenio DZ. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. Am J Physiol - Regul Integr Comp Physiol. 2011;300(5):R1126\u201333. https:\/\/doi.org\/10.1152\/ajpregu.00687.2010.","journal-title":"Am J Physiol - Regul Integr Comp Physiol"},{"issue":"4","key":"4068_CR10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jcsm.12434","volume":"10","author":"Y Hong","year":"2019","unstructured":"Hong Y, Lee JH, Jeong KW, Choi CS, Jun H. Amelioration of muscle wasting by glucagon-like peptide\u20101 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle. 2019;10(4):903\u201318. https:\/\/doi.org\/10.1002\/jcsm.12434.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"4068_CR11","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/jcsm.13025","volume":"13","author":"M Kamiya","year":"2022","unstructured":"Kamiya M, Mizoguchi F, Yasuda S. Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis. J Cachexia Sarcopenia Muscle. 2022;13(4):2118\u201331. https:\/\/doi.org\/10.1002\/jcsm.13025.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"4068_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.semnephrol.2013.04.004","volume":"33","author":"CJ Cheng","year":"2013","unstructured":"Cheng CJ, Kuo E, Huang CL. Extracellular potassium homeostasis: Insights from hypokalemic periodic paralysis. Semin Nephrol. 2013;33(3):237\u201347. https:\/\/doi.org\/10.1016\/j.semnephrol.2013.04.004.","journal-title":"Semin Nephrol"},{"issue":"1 Pt 1","key":"4068_CR13","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1152\/ajpendo.1985.249.1.E17","volume":"249","author":"K Zierler","year":"1985","unstructured":"Zierler K, Rogus EM, Scherer RW, Wu FS. Insulin action on membrane potential and glucose uptake: Effects of high potassium. Am J Physiol. 1985;249(1 Pt 1):E17\u201325. https:\/\/doi.org\/10.1152\/ajpendo.1985.249.1.E17.","journal-title":"Am J Physiol"},{"issue":"11","key":"4068_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"4068_CR15","unstructured":"Wingless-type. MMTV integration site family member 5a: A novel biomarker regulated in type 2 diabetes mellitus and diabetic kidney disease \u2014 King\u2019s College London. Accessed 4 Apr, 2024. https:\/\/kclpure.kcl.ac.uk\/portal\/en\/publications\/wingless-type-mmtv-integration-site-family-member-5a-a-novel-biom"},{"issue":"3","key":"4068_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/ijms20030562","volume":"20","author":"J Liu","year":"2019","unstructured":"Liu J, Liu Z. Muscle insulin resistance and the inflamed microvasculature: Fire from within. Int J Mol Sci. 2019;20(3):562. https:\/\/doi.org\/10.3390\/ijms20030562.","journal-title":"Int J Mol Sci"},{"issue":"Pt 17","key":"4068_CR17","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1113\/JP270371","volume":"593","author":"L Zhao","year":"2015","unstructured":"Zhao L, Fu Z, Wu J, et al. Globular adiponectin ameliorates metabolic insulin resistance via AMPK-mediated restoration of microvascular insulin responses. J Physiol. 2015;593(Pt 17):4067\u201379. https:\/\/doi.org\/10.1113\/JP270371.","journal-title":"J Physiol"},{"key":"4068_CR18","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.2147\/DDDT.S381546","volume":"16","author":"Q Ren","year":"2022","unstructured":"Ren Q, Chen S, Chen X, et al. An effective Glucagon-Like Peptide-1 receptor agonists, semaglutide, improves sarcopenic obesity in obese mice by modulating skeletal muscle metabolism. Drug Des Devel Ther. 2022;16:3723\u201335. https:\/\/doi.org\/10.2147\/DDDT.S381546.","journal-title":"Drug Des Devel Ther"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04068-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04068-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04068-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:28:18Z","timestamp":1744165698000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04068-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4068"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04068-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4908191\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written Informed Consent for the clinical details was obtained by the participant prior to writing of the paper in accordance with the Baystate ethics principals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written Informed consent for the clinical details was obtained by all participants prior to writing of the paper in accordance with the Baystate ethics principals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}